Sunday 24 June 2018 ,
Sunday 24 June 2018 ,
Latest News
  • Erdogan faces major test as turkey votes
  • Kroos strike at death helps Germany rescue WC hopes
  • 14 killed in shooting attacks in Mexican border city
  • ‘Robber’ killed in Pabna ‘gunfight’
  • Campaigning ends tonight
21 May, 2018 00:00 00 AM

FDA approves Retacrit (epoetin alfa-epbx) as First Epoetin Alfa Biosimilar for the treatment of anemia

FDA
FDA approves Retacrit (epoetin alfa-epbx) as First Epoetin Alfa Biosimilar for the treatment of anemia

The U.S. Food and Drug Administration recently approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery.

“It is important for patients to have access to safe, effective and affordable biological products and we are committed to facilitating the development and approval of biosimilar and interchangeable products,” said Leah Christl, Ph.D., director of the Therapeutic Biologics and Biosimilars Staff in the FDA’s Center for Drug Evaluation and Research. “Biosimilars can provide greater access to treatment options for patients, increasing competition and potentially lowering costs.”

Biological products are generally derived from a living organism and can come from many sources, such as humans, animals, microorganisms or yeast. A biosimilar is a biological product that is approved based on data showing that it is highly similar to a biological product already approved by the FDA (reference product) and has no clinically meaningful differences in terms of safety, purity and potency (i.e., safety and effectiveness) from the reference product, in addition to meeting other criteria specified by law.

The FDA’s approval of Retacrit is based on a review of evidence that included extensive structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data and other clinical safety and effectiveness data that demonstrates Retacrit is biosimilar to Epogen/Procrit. Retacrit has been approved as a biosimilar, not as an interchangeable product.

The most common side effects of epoetin alfa-treated patients in clinical studies of the reference product were high blood pressure, joint pain, muscle spasm, fever, dizziness, medical device malfunction, blood vessel blockage, respiratory infection, cough, rash, injection site irritation, nausea, vomiting, muscle pain, inflammation of the mouth and lips, weight decrease, reduction in white blood cells, bone pain, high blood sugar, insomnia, headache, depression, difficulty swallowing, low blood potassium, blood clots, itching, headache, injection site pain and chills.

Like Epogen/Procrit, Retacrit must be dispensed with a patient Medication Guide that provides information about the drug’s uses and risks. In addition, as with Epogen/Procrit, Retacrit contains a Boxed Warning to alert health care professionals and patients about increased risks of death, heart problems, stroke and tumor growth or recurrence. Additional warnings include high blood pressure, seizures, a condition in which the bone marrow stops making red blood cells thus causing anemia, serious allergic reactions and severe skin reactions.

The FDA granted approval of Retacrit to Hospira Inc., a Pfizer company.

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Men’s Health is as complex as women’s health. When we consider men’s health we often assume that they need to visit their doctors only…
It’s up to doctors to behave with integrity when charging patients

It’s up to doctors to behave with integrity when charging patients

Apatient, only described as aggrieved, is ushered into my room before I have had a chance to find out more. She is a woman in her early 30s, accompanied…
Q & A: Men’s health

Q & A: Men’s health

Do treatments for thinning hair and baldness really work? If you’re seeing more of your balding scalp every morning in the bathroom mirror -- and…
Male infertility

Male infertility

Mayo Clinic Staff Approximately 15 percent of couples are infertile. This means they aren't able to conceive a child even though they've had frequent,…
Warning signs of male menopause

Warning signs of male menopause

Megan McCrea As you dig deeper, you’ll learn that the condition is quite controversial. Health experts argue about every aspect of “male menopause:”…
The men’s health gap: men must be included in the global health equity agenda

The men’s health gap: men must be included in the global health equity agenda

In most parts of the world, health outcomes among boys and men continue to be substantially worse than among girls and women, yet this gender-based disparity…
Syphilis and gonorrhoea up by one-fifth

Syphilis and gonorrhoea up by one-fifth

England has continued to see a rise in cases of syphilis and gonorrhoea over the past year. New data shows a 20% increase in cases of syphilis and a 22%…
Affliction struck by plastic toys to kid’s health

Affliction struck by plastic toys to kid’s health

Children health and growth are momentous because they will be the future leaders of nation. There are many factors that influence their appropriate physical…
How alcohol affects your body

How alcohol affects your body

Thirty seconds after your first sip, alcohol races into your brain. It slows down the chemicals and pathways that your brain cells use to send messages.…
Millions could have incorrect statin, aspirin and blood pressure prescriptions

Millions could have incorrect statin, aspirin and blood pressure prescriptions

More than 11 million Americans may have incorrect prescriptions for aspirin, statins and blood pressure medications, according to a study led by researchers…
FDA approves Yonsa (abiraterone acetate) to treat Metastatic Castration-Resistant Prostate Cancer

FDA approves Yonsa (abiraterone acetate) to treat Metastatic Castration-Resistant Prostate Cancer

Sun Pharmaceutical Industries Ltd. and includes its subsidiaries and/or associate companies) and Churchill Pharmaceuticals, LLC. (Churchill) recently…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting